IL-17A inhibitor switching – Efficacy of ixekizumab following secukinumab failure. A single-center experience
- Shany Sherman
- , Efrat Solomon-Cohen
- , Iris Amitay-Laish
- , Emmilia Hodak
- , Lev Pavlovsky*
*Corresponding author for this work
- Rabin Medical Center Israel
- Tel Aviv University
Research output: Contribution to journal › Comment/debate
24
Scopus
citations